<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01427881</url>
  </required_header>
  <id_info>
    <org_study_id>2541.00</org_study_id>
    <secondary_id>NCI-2011-02459</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01427881</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies</brief_title>
  <official_title>A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well cyclophosphamide works in preventing chronic
      graft-versus-host disease after allogeneic peripheral blood stem cell transplant in patients
      with hematological malignancies. Giving chemotherapy and total-body irradiation before
      transplantation helps stop the growth of cancer cells and prevents the patient's immune
      system from rejecting the donor's stem cells. Healthy stem cells from a donor that are
      infused into the patient help the patient's bone marrow make blood cells; red blood cells,
      white blood cells, and platelets. Sometimes, however, the transplanted donor cells can cause
      an immune response against the body's normal cells, which is called graft-versus-host disease
      (GVHD). Giving cyclophosphamide after transplant may prevent this from happening or may make
      chronic GVHD less severe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. The primary objective of this study is to assess outcomes when high-dose cyclophosphamide
      (CY) is administered on days 3 and 4 followed by cyclosporine (CSP) after human leukocyte
      antigen (HLA)-matched related or unrelated mobilized blood cell transplantation with
      total-body irradiation (TBI) or busulfan (BU)-based conditioning.

      SECONDARY OBJECTIVES:

      I. The secondary objective of this study is to assess hematopoietic cell transplantation
      (HCT) outcomes when withdrawal of CSP is accelerated in patients without acute
      graft-versus-host disease (GVHD).

      OUTLINE: Patients' conditioning regimens are determined by the Clinical Coordinator after
      consultation with the attending physician. Based on disease, patients receive either TBI or
      fludarabine and busulfan.

      PREPARATIVE REGIMEN: Patients receive TBI twice daily (BID) on days -4 or -3 to -1. Some
      patients also receive fludarabine intravenously (IV) daily on days -5 to -2 and busulfan IV
      over 3 hours once daily (QD) or over 2 hours every 6 hours on days -5 to -2. Patients may
      also undergo central nervous system (CNS) prophylaxis, testicular irradiation, and/or
      involved field irradiation as per standard practice.

      TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation
      (PBSCT) on day 0 per standard practice.

      GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients
      also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on
      days 56-126.

      Treatment continues in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at day 180 and then annually
      for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chronic GVHD Requiring Systemic Immunosuppressive Treatment</measure>
    <time_frame>At 1 year after transplantation</time_frame>
    <description>Chronic GVHD will be defined by National Institutes of Health (NIH) criteria and requiring systemic treatment. A reduction in the cumulative incidence of GVHD from ~35% to ~15% at 1 year would represent a reasonable goal. A sample size of 42 patients provides 90% power to observe such a difference with one-side 5% type-1 error.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Donor Engraftment</measure>
    <time_frame>At day 28</time_frame>
    <description>Donor engraftment is defined as the count (percent) of patients with full donor chimerism. Full donor chimerism is defined as at least 95% donor CD3 cells in peripheral blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grades II-IV and III-IV Acute GVHD</measure>
    <time_frame>Through day +100 post-transplant</time_frame>
    <description>Grades II-IV and III-IV GVHD will be assessed with the use of cumulative incidence plots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Systemic Immunosuppressive Treatment</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The need for additional immunosuppressive treatment with agents other than those used for prophylaxis, the reasons for their administration (acute GVHD, chronic GVHD, or other reasons) and the duration of its administration will be determined. Patients will be monitored to determine the duration of systemic immunosuppressive treatment. Primary and secondary treatment of acute GVHD and withdrawal of systemic immunosuppressive treatment will be assessed with the use of cumulative incidence plots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent or Recurrent Malignancy After HCT</measure>
    <time_frame>At 2 years</time_frame>
    <description>Recurrent or progressive malignancy will be assessed with the use of cumulative incidence plots. Recurrent malignancy will be defined by hematologic criteria. Recurrent malignancy will also be defined as any unplanned medical intervention designed to prevent progression of malignant disease in patients who have molecular, cytogenetic or flow-cytometric evidence of malignant cells after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality</measure>
    <time_frame>At 2 years</time_frame>
    <description>Defined as death in the absence of recurrent or progressive malignancy after HCT. Non-relapse morality will be assessed with the use of cumulative incidence plots. This secondary endpoint will be characterized and presented as a cumulative incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At 1 year post-transplant</time_frame>
    <description>Overall survival will be evaluated as Kaplan-Meier estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>At 1 year post-transplant</time_frame>
    <description>Disease-free survival will be evaluated as Kaplan-Meier estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Recovery</measure>
    <time_frame>Up to day +100</time_frame>
    <description>Descriptive statistics will be used to assess the median days of neutrophil and platelet recovery. The day of neutrophil recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the absolute neutrophil count is &gt; 500/uL. The day of platelet recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the platelet count is &gt;= 20,000/uL without platelet transfusion support in the seven days prior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Failure</measure>
    <time_frame>By greater than or equal to 28 days post-transplant</time_frame>
    <description>Descriptive statistics will be used to assess the incidence of primary graft failure and secondary graft failure. Primary graft failure is defined as failure to achieve a sustained neutrophil count of &gt;= 500/uL by &gt;= 28 days post-transplant. Secondary graft failure is defined as the decline in neutrophil count to &lt; 500/uL after achieving engraftment which is unrelated to infection or drug effect and is unresponsive to stimulation by growth factors.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Megakaryoblastic Leukemia (M7)</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Erythroleukemia (M6a)</condition>
  <condition>Adult Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Adult Pure Erythroid Leukemia (M6b)</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Acute Erythroleukemia (M6)</condition>
  <condition>Childhood Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Childhood Acute Megakaryocytic Leukemia (M7)</condition>
  <condition>Childhood Acute Myeloid Leukemia in Remission</condition>
  <condition>Childhood Burkitt Lymphoma</condition>
  <condition>Childhood Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Diffuse Large Cell Lymphoma</condition>
  <condition>Childhood Immunoblastic Large Cell Lymphoma</condition>
  <condition>Childhood Myelodysplastic Syndromes</condition>
  <condition>Childhood Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Cutaneous B-cell Non-Hodgkin Lymphoma</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Hepatosplenic T-cell Lymphoma</condition>
  <condition>Intraocular Lymphoma</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Noncutaneous Extranodal Lymphoma</condition>
  <condition>Peripheral T-cell Lymphoma</condition>
  <condition>Philadelphia Chromosome Negative Chronic Myelogenous Leukemia</condition>
  <condition>Post-transplant Lymphoproliferative Disorder</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Childhood Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Childhood Small Noncleaved Cell Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Recurrent/Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <condition>Small Intestine Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <condition>Testicular Lymphoma</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)</arm_group_label>
    <other_name>ciclosporin</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo allogeneic PBSCT</description>
    <arm_group_label>Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo allogeneic PBSCT</description>
    <arm_group_label>Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute lymphocytic leukemia (ALL) in morphologic first complete remission (CR1) with
             high risk features defined as, but not limited to: evidence of adverse cytogenetics
             such as t(9;22), t(1;19), t(4;11), or mixed-lineage leukemia (MLL) rearrangements;
             presence of minimal residual disease; progenitor B-cell immunophenotype; high white
             blood cells (WBC) at diagnosis (&gt; 30,000/ul in B-ALL; &gt; 100,000/ul in T-ALL); or
             delayed attainment of CR (&gt; 4 weeks) after induction therapy; additional clinical
             characteristics deemed to confer a high relapse risk may be discussed with and
             approved by the Principal Investigator (PI)

          -  Acute myeloid leukemia (AML) in CR1 EXCEPT patients with low-risk features defined as:

               -  Inv 16 or t(8;21) in the absence of c-kit mutations

               -  Normal karyotype who are FLT3-ITD-negative and NPM1-positive in the absence of
                  c-kit mutations

               -  Patients with respective &quot;low-risk&quot; features are eligible, however, if (i) more
                  than 1 cycle of induction therapy was required to achieve CR1 (ii) the patient
                  had a preceding myelodysplastic syndrome (MDS) other than myelofibrosis, or (iii)
                  secondary AML

          -  Acute leukemia in 2nd or greater CR (CR &gt;= 2)

          -  Refractory or relapsed AML with =&lt; 10% bone marrow blasts and no circulating blasts or
             proven extramedullary disease

          -  AML transformed from myelodysplastic syndrome (MDS) with &lt; 10% bone marrow blasts

          -  MDS with following high risk features:

               -  High risk cytogenetics (including, but not limited to: 7q--, inv[3], t[3q],
                  del[3q] or complex karyotype)

               -  International Prognostic Scoring System (IPSS) intermediate (INT)-2 or greater

               -  Treatment-related MDS

               -  Any phase of MDS if patient is &lt; 21 years of age

          -  Chronic myelogenous leukemia (CML) beyond 1st chronic phase or resistant or intolerant
             to tyrosine kinase inhibitors (adults) or any phase (pediatric &lt; 21 years)

          -  Chronic myelomonocytic leukemia

          -  Philadelphia-negative myeloproliferative disorder

          -  Lymphoma: relapsed chemotherapy-sensitive (complete or partial response) Hodgkin or
             non-Hodgkin lymphoma

          -  Multiple myeloma-stage III

          -  The patient or legal representative must be able to understand and give written
             informed consent

          -  DONORS: The donor must be a genotypically HLA-identical sibling, a phenotypically
             HLA-matched first-degree relative, or an unrelated donor who is molecularly matched
             with the patient at HLA-A, B, C, DRB1

          -  DONORS: Donors must meet the selection criteria for administration of G-CSF
             (filgrastim) and apheresis defined by the Foundation for the Accreditation of Cell
             Therapy (FACT) and will be screened per the American Association of Blood Banks (AABB)

          -  DONORS: Donors must be capable of giving informed consent

        Exclusion Criteria:

          -  Prior autologous or allogeneic stem cell transplant

          -  Performance status &gt; 2 (Eastern Cooperative Oncology Group [ECOG]) or &lt; 50 (Lansky;
             for patients &lt; 16 years old)

          -  Uncontrolled infection; the protocol principal investigator (PI) will be final arbiter
             if there is uncertainty regarding whether a previous infection is under adequate
             control to allow enrollment in the study

          -  Positive serology for human immunodeficiency virus (HIV)-1, 2 or human T cell
             lymphotropic virus (HTLV)-1, 2

          -  Left ventricular ejection fraction &lt; 45% or shortening fraction &lt; 25%; no uncontrolled
             arrhythmias or symptomatic cardiac disease

          -  Symptomatic pulmonary disease; forced expiratory volume in one second (FEV1), forced
             vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO) =&lt; 50%
             of predicted (corrected for hemoglobin); if pulmonary function tests cannot be
             performed, an oxygen saturation &lt; 92% on room air

          -  Calculated (Cockcroft-Gault or appropriate calculation for pediatric patients) serum
             creatinine clearance =&lt; 60 mL/min; if the calculated CrCl is 50-60 mL/min, but a
             measured CrCl by 24 hour urine collection is &gt; 60 mL/min, this measurement is
             acceptable

          -  Total serum bilirubin more than twice upper normal limit

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 3-fold
             higher than laboratory upper normal limits

          -  Female patient must have negative serum pregnancy test (all women of child
             bearing-potential must have test performed)

          -  DONORS: Potential donors who for psychological, physiological, or medical reasons
             cannot tolerate administration of G-CSF or apheresis

          -  DONORS: Donors who are allergic to filgrastim or Escherichia (E.) coli-derived
             proteins

          -  DONORS: Donor-related risks to recipients

          -  DONORS: Positive anti-donor lymphocytotoxic crossmatch

          -  DONORS: Donors who are positive for HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Mielcarek</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2011</study_first_submitted>
  <study_first_submitted_qc>September 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2011</study_first_posted>
  <results_first_submitted>April 11, 2017</results_first_submitted>
  <results_first_submitted_qc>May 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2017</results_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Marco Mielcarek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Intraocular Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)</title>
          <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.
cyclophosphamide: Given IV
cyclosporine: Given IV
peripheral blood stem cell transplantation: Undergo allogeneic PBSCT
total-body irradiation: Undergo TBI
fludarabine phosphate: Given IV
busulfan: Given IV
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)</title>
          <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.
cyclophosphamide: Given IV
cyclosporine: Given IV
peripheral blood stem cell transplantation: Undergo allogeneic PBSCT
total-body irradiation: Undergo TBI
fludarabine phosphate: Given IV
busulfan: Given IV
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="3" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Chronic GVHD Requiring Systemic Immunosuppressive Treatment</title>
        <description>Chronic GVHD will be defined by National Institutes of Health (NIH) criteria and requiring systemic treatment. A reduction in the cumulative incidence of GVHD from ~35% to ~15% at 1 year would represent a reasonable goal. A sample size of 42 patients provides 90% power to observe such a difference with one-side 5% type-1 error.</description>
        <time_frame>At 1 year after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)</title>
            <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.
cyclophosphamide: Given IV
cyclosporine: Given IV
peripheral blood stem cell transplantation: Undergo allogeneic PBSCT
total-body irradiation: Undergo TBI
fludarabine phosphate: Given IV
busulfan: Given IV
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic GVHD Requiring Systemic Immunosuppressive Treatment</title>
          <description>Chronic GVHD will be defined by National Institutes of Health (NIH) criteria and requiring systemic treatment. A reduction in the cumulative incidence of GVHD from ~35% to ~15% at 1 year would represent a reasonable goal. A sample size of 42 patients provides 90% power to observe such a difference with one-side 5% type-1 error.</description>
          <units>percent of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="5" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Engraftment</title>
        <description>Donor engraftment is defined as the count (percent) of patients with full donor chimerism. Full donor chimerism is defined as at least 95% donor CD3 cells in peripheral blood.</description>
        <time_frame>At day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)</title>
            <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.
cyclophosphamide: Given IV
cyclosporine: Given IV
peripheral blood stem cell transplantation: Undergo allogeneic PBSCT
total-body irradiation: Undergo TBI
fludarabine phosphate: Given IV
busulfan: Given IV
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Engraftment</title>
          <description>Donor engraftment is defined as the count (percent) of patients with full donor chimerism. Full donor chimerism is defined as at least 95% donor CD3 cells in peripheral blood.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grades II-IV and III-IV Acute GVHD</title>
        <description>Grades II-IV and III-IV GVHD will be assessed with the use of cumulative incidence plots.</description>
        <time_frame>Through day +100 post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)</title>
            <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.
cyclophosphamide: Given IV
cyclosporine: Given IV
peripheral blood stem cell transplantation: Undergo allogeneic PBSCT
total-body irradiation: Undergo TBI
fludarabine phosphate: Given IV
busulfan: Given IV
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Grades II-IV and III-IV Acute GVHD</title>
          <description>Grades II-IV and III-IV GVHD will be assessed with the use of cumulative incidence plots.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grades II-IV GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grades III-IV GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Systemic Immunosuppressive Treatment</title>
        <description>The need for additional immunosuppressive treatment with agents other than those used for prophylaxis, the reasons for their administration (acute GVHD, chronic GVHD, or other reasons) and the duration of its administration will be determined. Patients will be monitored to determine the duration of systemic immunosuppressive treatment. Primary and secondary treatment of acute GVHD and withdrawal of systemic immunosuppressive treatment will be assessed with the use of cumulative incidence plots.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>This data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)</title>
            <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.
cyclophosphamide: Given IV
cyclosporine: Given IV
peripheral blood stem cell transplantation: Undergo allogeneic PBSCT
total-body irradiation: Undergo TBI
fludarabine phosphate: Given IV
busulfan: Given IV
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Systemic Immunosuppressive Treatment</title>
          <description>The need for additional immunosuppressive treatment with agents other than those used for prophylaxis, the reasons for their administration (acute GVHD, chronic GVHD, or other reasons) and the duration of its administration will be determined. Patients will be monitored to determine the duration of systemic immunosuppressive treatment. Primary and secondary treatment of acute GVHD and withdrawal of systemic immunosuppressive treatment will be assessed with the use of cumulative incidence plots.</description>
          <population>This data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistent or Recurrent Malignancy After HCT</title>
        <description>Recurrent or progressive malignancy will be assessed with the use of cumulative incidence plots. Recurrent malignancy will be defined by hematologic criteria. Recurrent malignancy will also be defined as any unplanned medical intervention designed to prevent progression of malignant disease in patients who have molecular, cytogenetic or flow-cytometric evidence of malignant cells after transplantation.</description>
        <time_frame>At 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)</title>
            <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.
cyclophosphamide: Given IV
cyclosporine: Given IV
peripheral blood stem cell transplantation: Undergo allogeneic PBSCT
total-body irradiation: Undergo TBI
fludarabine phosphate: Given IV
busulfan: Given IV
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Persistent or Recurrent Malignancy After HCT</title>
          <description>Recurrent or progressive malignancy will be assessed with the use of cumulative incidence plots. Recurrent malignancy will be defined by hematologic criteria. Recurrent malignancy will also be defined as any unplanned medical intervention designed to prevent progression of malignant disease in patients who have molecular, cytogenetic or flow-cytometric evidence of malignant cells after transplantation.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="5" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Mortality</title>
        <description>Defined as death in the absence of recurrent or progressive malignancy after HCT. Non-relapse morality will be assessed with the use of cumulative incidence plots. This secondary endpoint will be characterized and presented as a cumulative incidence.</description>
        <time_frame>At 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)</title>
            <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.
cyclophosphamide: Given IV
cyclosporine: Given IV
peripheral blood stem cell transplantation: Undergo allogeneic PBSCT
total-body irradiation: Undergo TBI
fludarabine phosphate: Given IV
busulfan: Given IV
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality</title>
          <description>Defined as death in the absence of recurrent or progressive malignancy after HCT. Non-relapse morality will be assessed with the use of cumulative incidence plots. This secondary endpoint will be characterized and presented as a cumulative incidence.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="4" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival will be evaluated as Kaplan-Meier estimates.</description>
        <time_frame>At 1 year post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)</title>
            <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.
cyclophosphamide: Given IV
cyclosporine: Given IV
peripheral blood stem cell transplantation: Undergo allogeneic PBSCT
total-body irradiation: Undergo TBI
fludarabine phosphate: Given IV
busulfan: Given IV
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival will be evaluated as Kaplan-Meier estimates.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6" lower_limit="63.5" upper_limit="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <description>Disease-free survival will be evaluated as Kaplan-Meier estimates.</description>
        <time_frame>At 1 year post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)</title>
            <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.
cyclophosphamide: Given IV
cyclosporine: Given IV
peripheral blood stem cell transplantation: Undergo allogeneic PBSCT
total-body irradiation: Undergo TBI
fludarabine phosphate: Given IV
busulfan: Given IV
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Disease-free survival will be evaluated as Kaplan-Meier estimates.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="61.6" upper_limit="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematologic Recovery</title>
        <description>Descriptive statistics will be used to assess the median days of neutrophil and platelet recovery. The day of neutrophil recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the absolute neutrophil count is &gt; 500/uL. The day of platelet recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the platelet count is &gt;= 20,000/uL without platelet transfusion support in the seven days prior.</description>
        <time_frame>Up to day +100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)</title>
            <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.
cyclophosphamide: Given IV
cyclosporine: Given IV
peripheral blood stem cell transplantation: Undergo allogeneic PBSCT
total-body irradiation: Undergo TBI
fludarabine phosphate: Given IV
busulfan: Given IV
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Hematologic Recovery</title>
          <description>Descriptive statistics will be used to assess the median days of neutrophil and platelet recovery. The day of neutrophil recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the absolute neutrophil count is &gt; 500/uL. The day of platelet recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the platelet count is &gt;= 20,000/uL without platelet transfusion support in the seven days prior.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutrophil Engraftment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="16" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Engraftment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="10" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Failure</title>
        <description>Descriptive statistics will be used to assess the incidence of primary graft failure and secondary graft failure. Primary graft failure is defined as failure to achieve a sustained neutrophil count of &gt;= 500/uL by &gt;= 28 days post-transplant. Secondary graft failure is defined as the decline in neutrophil count to &lt; 500/uL after achieving engraftment which is unrelated to infection or drug effect and is unresponsive to stimulation by growth factors.</description>
        <time_frame>By greater than or equal to 28 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)</title>
            <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.
cyclophosphamide: Given IV
cyclosporine: Given IV
peripheral blood stem cell transplantation: Undergo allogeneic PBSCT
total-body irradiation: Undergo TBI
fludarabine phosphate: Given IV
busulfan: Given IV
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Failure</title>
          <description>Descriptive statistics will be used to assess the incidence of primary graft failure and secondary graft failure. Primary graft failure is defined as failure to achieve a sustained neutrophil count of &gt;= 500/uL by &gt;= 28 days post-transplant. Secondary graft failure is defined as the decline in neutrophil count to &lt; 500/uL after achieving engraftment which is unrelated to infection or drug effect and is unresponsive to stimulation by growth factors.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For all-cause mortality: 1 year after transplant For adverse events and serious adverse events, not mortality, will be monitored and recorded through the time of discharge from the transplant center</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)</title>
          <description>PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.
TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.
cyclophosphamide: Given IV
cyclosporine: Given IV
peripheral blood stem cell transplantation: Undergo allogeneic PBSCT
total-body irradiation: Undergo TBI
fludarabine phosphate: Given IV
busulfan: Given IV
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Infection/Fever</sub_title>
                <description>Various organs (blood, pulmonary, bladder, etc)</description>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Disease recurrence/MRD</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Delayed engraftment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Graft failure/poor graft function</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>GVHD</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>RS3PE (rheumatologic)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory (not infection)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthastic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to engraft by day 28</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart failure or LV dysfunction (grade 3-5)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Persistent n/v thru day 28 and not related to GVHD</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Mucositis (grade 3-5; requiring TPN)</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other (grade 3-5)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis or hematuria (grade 2-5; not infection)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marco Mielcarek, MD</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-2827</phone>
      <email>mmielcar@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

